Dear Valued Stakeholders,
As we work to develop new cancer treatments for patients, I would first like to thank you for your ongoing support of OncoSec’s programs and business strategy. We are committed to providing timely corporate updates, including recent achievements and upcoming milestones. We are pleased to provide brief recaps of our conference calls to further expand our avenues of communication. We hope these continued activities further enhance shareholder engagement.
Over this past quarter, we’ve announced positive pre-clinical and clinical data as well as significant advancements in the field of gene electro-transfer. I hope you find these updates informative, and I look forward to sharing more information with you throughout the year. Thank you again for your ongoing confidence in OncoSec as we continue to advance our immuno-oncology pipeline.
President and CEO